Immune checkpoint inhibitors, such as anti-PD1/PD-L1 antibodies, have changed the treatment of several cancers.The survival of cancer patients has drastically improved, with some of them showing complete and durable responses. A number of patients are likely to be cured of their metastatic cancer. This should encourage further research from academic or pharmaceutical teams in an effort to increase the efficacy of modern immunotherapy.
Key Words
Immunotherapy, melanoma, PD-1, lymphocytes